In preparation to list Med-X, Inc. shares on a public exchange, the management team has reserved the Nasdaq ticker symbol, (MXRX).
Recently the Company secured a $100 million capital commitment from Global Emerging Markets, a Luxembourg-based alternative investment group worth $3.4 billion. The investment banking community has recognized the continued demand for the Med-X product selection as well as large investor demand to participate in investment strategies that make an impact on health and ecology. The company investor base has surpassed 3,800 stakeholders which has supported the Company’s mission since inception. Now that the Company has secured large scale capital to advance the business model, management is negotiating with investment banking community players to Underwrite and Initial Public Offering.
Now you can join the Green Scene movement that is making a difference in the areas of Health, Wellness and Ecology everyday, while management prepares the Company for expansion. This round of Regulation A+ crowdfunding will continue to support revenue growth of its brand portfolio, develop exciting new products and pursue acquisition opportunities, as the Company continues to draw awareness of the overuse of toxic synthetic chemicals and addictive pharmaceutical products.
RAISED TO DATE
CURRENT PRICE PER SHARE
CURRENT MINIMUM INVESTMENT
Pest Control, Healthcare, Emerging
PATH TO LIQUIDITY
Nearly everyone on this planet is exposed to pesticides or has taken a pain relief pill, yet science has proven the long-term risks of these products on one’s health and the environment. Too few people are aware that green scene products exist that do the same job as outdated traditional chemical products do, with equal efficacy.
Reports estimate that in the United States alone over 20 billion pounds of pesticides have been sprayed on our properties and food in just the last 20 years. Globally in the same timespan, this industry has generated more than $1 trillion in revenues. So, why are we all so exposed?
Millions of Pounds of Pesticides
Continue to be Sprayed Each Year
Historically, the pest management industry has been controlled by a small group of very large and powerful international chemical corporations. These corporations hold patents and spend millions of dollars lobbying governments all over the world to make sure their synthetic pesticides are deemed “safe for use”, even though the long-term effects from exposure have been proven to be unhealthful and dangerous.
Most of these synthetic pesticides contain strong toxic/poisonous chemicals with proven long-lasting, devastating carcinogenic effects. These compounds can take generations to become nascent in the environment. As more chemicals are sprayed or used in products, the resulting pollution compounds to increasingly harm people and the environment.
Chemicals from plastics and pesticides are now beginning to be found in our groundwater and public drinking water supplies for the first time. No wonder numerous studies are now linking diseases such as Parkinson’s disease, asthma, cancer and reproductive dysfunction to chemical pesticides.
We all know a family impacted by the Opioid Epidemic. For years, pharmaceutical conglomerates have lobbied for lower thresholds on drug regulation, knowing full well the addictive nature of opioids. These addictive drugs have been marketed for the use of everyday pain relief, even though science clearly proves the addictive nature of the chemicals used to make them. For a person born in 2017 the odds of dying from an opioid overdose is now higher than dying in a car accident.
29% OF ALL PEOPLE WHO ARE PRESCRIBED OPIOIDS END UP MISUSING THEM AND 12% OF ALL PEOPLE PRESCRIBED OPIOIDS BECOME ADDICTED
Making a Difference, One Community at a Time.
Med-X, Inc. is an innovator and leader in developing all-natural alternative solutions to the outdated poisonous chemicals and harmful pharmaceutical products often used in pest control and pain management. Med-X incorporates best-in-class science, research and technology for manufacturing and service capabilities across pest control, pain management and aromatherapy by primarily utilizing essential oil product development.
The company’s sales are represented by multiple commercial sales verticals and third-party service providers managed through various domestic and international distribution partners. Retail sales are currently conducted by over-the-counter pharmacy retailers and various e-commerce service providers. Med-X is also focused on educating the public through its digital media platform The National Investor Network.
Through our health-conscious, eco-friendly products, we’re creating a safer, greener world for years to come. Independent toxicity studies have proven that our products come with a greatly reduced risk of cancer and other chronic diseases. And because they’re made with plants, they cause little to no harm to the environment as they do to you.
Med-X has built a portfolio of high margin commercial and consumer product brands as well as professional pest control service products. These proven brands help drive the company’s current revenue. This portfolio strategy gives the company the flexibility and power to scale up operations and raise revenues in any sector by acquiring other like-minded brands who want the opportunity to grow alongside us. The company is already in talks with several small to medium-sized companies who have shown interest in being a part of a bigger green movement.
Going Forward Strategy
Nature-Cide Products & Services
We plan to expand our market position with commercial advertising and expanded distribution of the Nature-Cide product lines for continued sale in Commercial Pest Control, Hospitality, Janitorial, Transportation, Housing Authorities, School Districts, Turf-Care and Agriculture. We will also be preparing several Nature-Cide Ready to Use SKUs for consumer use to be primarily positioned in various Big Box retail stores.
The Nature-Cide service division plans to continue to grow it’s footprint across the U.S. and globally as the management team continues to aggressively push to increase revenues and market share by acquiring unique pest control service companies and injecting the Nature-Cide and Integrated Pest Management models into their existing book of business.
Our pest control technology and service methods are not just limited to the ground, we are currently testing drone delivery systems of our all-natural pesticides and granular product – stay tuned for updates on this exciting development.
Thermal-Aid and Malibu Brands Products
We are looking to expand the market presence of Thermal-Aid in Pain Management sectors including insurance coverage segments for Physical Therapy, Flexible Spending, and Patient Care, while also continuing the expansion of its retail footprint within the OTC Pharmacy space.
As we continue placement of our consumer products in the retail markets, that comes with expanding our e-commerce positioning. Our Malibu Brands line of products has launched its first topical pain management products call “Pacific Pain Relief Cream”, which is now available via ecomerrce. Management expects to take advantage of the OTC Pharmacy footprint that currently surrounds the Thermal-Aid brand, to further position Malibu Brands into the pain management markets.
National Pest Control And Healthcare Distribution
Nature-Cide is being used by a growing network of commercial customers including licensed commercial and residential pest control operators throughout the United States and beyond. Nature-Cide currently enjoys solid relations with the largest pest, turf and janitorial suppliers such as Target Specialty Products, Veseris here in the USA with new relations with Rentokil Initial in various regions including Asia and India.
The company plans to continue aggressively marketing within the Pest Control, Hospitality, Transportation, Agriculture, and Janitorial supply markets, while also pursuing the implementation of Nature-Cide products being used in state and federal facilities throughout various regions of the United States.
Pest Management Industry
- Growth: $18 billion in 2018 and expected to surge to $27 billion by 2025.
- Driving factors: government regulations on food hygiene, public health, environmental health, growing public awareness
- Restraining factors: lack of skilled technicians, delayed regulatory approval process for chemical products
- Opportunity: products that fall under the less-regulated FIFRA 25(b) Minimum Risk Pesticide category
Pain Management Industry
- Growth: $36.1 billion in 2017 and expected to grow to $52 billion by 2022.
- Driving factors: pain-causing diseases (e.g. multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, cancer), short-term (acute) pain and long-term (chronic) pain
- Restraining factors: addictive properties of chemical drugs, epidemic overdosage of prescription opiates.
- Opportunity: the need to improve service quality and safety for patients
As a member of the pest control community in emerging industries, the team hopes to expand its footprint in all emerging markets where all-natural solutions can play a role. Management believes that helping innovate and streamline all types of applications used within farming, hospitality and janitorial operations will pave the way for continued product development and revenue growth.
The Company and parts of management hold application licenses in California for various types of pest control and are trained and proficient in several types of agriculture. Multiple staff members are also proficient in supercritical CO2 extraction of all types of essential oils, with a focus on the pest control and pain management sectors.
Currently Nature-Cide products are positioned in almost 40 distribution centers in various regions around the United States. These centers cater to large scale farming, green house, pest control, hospitality, turf and sanitation operations which depend on these types of centers for all of their equipment and supply needs. Nature-Cide products are used in everyday settings including in school districts, parks and recreation, zoos, all types of food production and farming, so having the ability for a professional service company to secure our products quickly has been one of the keys to opening the many avenues where all-natural solutions are becoming the new normal.
There is a very large demand for new effective all-natural solutions in both mainstream pest control and in the world of pharmaceuticals. The potential for the investor to prosper in these sectors is realistic. These markets are long overdue for new ideas and innovations and opportunities to invest in these markets are rare and difficult to come by for the working-class American.
An investment in Med-X, is the opportunity to get in on the ground floor of a company that is already disrupting these markets with green options. We know that a larger portion of the market shares in these industries must move to the safer, greener side and we are sitting perfectly and addressing the needs of the markets as consumers continue to demand alternative all-natural options.
We’re actively moving forward, negotiating with investment banks to underwrite and publicly list the company on the Nasdaq Exchange under our reserved symbol “MXRX.”
Our growth trajectory. We recently secured a $100 million capital commitment from Global Emerging Markets, a Luxembourg-based alternative investment group worth $3.4 billion. This is to be tapped soon after our shares are publicly listed. Management believes that this Regulation A+ Offering coupled with an Initial Public Offering could be the catalyst to bridge the gap from the private sector to access growth capital in the open market for years to come.
Matthew A. Mills
Matthew Mills is the Med-X, Inc. CEO and Chairman of the Board. Matthew is the Company’s visionary. He leverages his vast experience and knowledge in product development, operations, business development, manufacturing, marketing, and crowdfunding to position the company for short-term and long-term growth.
Dr. David Toomey
Dr. David Toomey has spent his professional life as a family physician for more than 24 years and as a Hospice Medical Director for the last decade. Over his many years as a physician, Dr. Toomey has also worked as a clinical investigator, developing and running clinical trials for multiple companies, including major pharmaceutical firms.
Ronald J. Tchorzewski
CFO and Director of Med-X, Inc. since its inception, Ron Tchorzewski boasts more than 35 years of experience in financial accounting for start-up and development companies, as well as reporting for publicly held companies from Silicon Valley and beyond. As Chief Financial Officer, his purview includes business plan development, capital structure, and day-to-day accounting, and he positions Med-X, Inc. for financial success.
Jennifer Mills is the President, Director, and Corporate Secretary of Med-X, Inc. She has worked for multiple companies in her career as a high-level accounting liaison, as well as in Human Resources and project management.
Nick Phillips began his career in the Hollywood entertainment world before moving into digital marketing for multiple products in Los Angeles. Now, he drives the Media Divisions at Med-X, Inc. His skill set, coupled with his dedication and attention to detail, ensures solid leadership for our Media and E-Commerce Divisions.
Dr. Allan Kurtz
Dr. Allan Kurtz is board-certified in internal medicine and has owned and operated a professional medical corporation, since 1986. Dr. Kurtz has been the Medical Director of both the Warner Medical Center and the California Center of Longevity and Functional Medicine. He is also a long-time member of the American Osteopathic College of Internal Medicine.
Dr. Morton Hyson
Dr. Morton Hyson is in private practice as a Board-certified Neurologist in Las Vegas, Nevada. He is also a Clinical Assistant Professor at Touro University in San Francisco, California, where he has been educating since September 2000. His professional affiliations include the American Medical Association, the American Academy of Neurology, the American Academy of Neurological and Orthopedic Surgeons, and the American Headache Society.
Frederick Dashiell, Jr.
Frederick Dashiell, Jr. has held various teaching positions at educational institutions such as Chapman University, California Institute of Technology, and University of California, Los Angeles. He has also held computer scientist and research scientist positions in the private sector. Mr. Dashiell received a Bachelor of Science in Physics from the University of North Carolina at Chapel Hill in 1963 and a Ph.D. in Mathematics from the University of California, Berkeley in 1973.
Frequently Asked Questions
Where are your figures sourced from?
What is Reg A+ Equity Crowdfunding?
In June 2015, the final Regulation A+ rules under Title IV of the JOBS Act of 2012 became effective, after approval by the Securities and Exchange Commission, paving the way for companies like Med-X, Inc. to raise up to $50 million from both accredited and non-accredited investors.
NEW: Med-X Engages with Investor Relations Group, MZ North America as Planning to Access the Awaiting $100MM in Capital from Global Emerging Markets Continues
In this company update, CEO, Matthew Mills informs the shareholders on the new relationship with Investor Relations Firm MZ North America. Matthew informs the shareholders on the company's continued focus to gain access to the $100 Million in capital from GEM. Matthew also discusses changes to the Board of Directors as well as an update on international sales and marketing opportunities.
Med-X, Inc. Receives Patent on Nature-Cide Insecticidal Soil
LOS ANGELES, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Med-X, Inc. (Med-X) announced that in October 2021 the Company received Patent No. 11,147,266 B2 for its Nature-Cide Insecticidal Soil formulation. What started as a soil application for the cannabis industry in 2016 has blossomed into a multi-use soil blend for all types of cultivation, from greenhouse and agricultural applications to cannabis/hemp operations.
Med-X, Inc. Relaunches its Regulation A+ Crowdfunding Offering in Preparation for a Public Market Listing to Access its $100 Million Capital Commitment
In this very important video update COO and President, Matthew Mills informs the shareholders on the positioning and the preparation to list the Company on a national exchange to access the $100 million capital commitment for expansion that's waiting in the open market for the Company. Matthew is actively engaging in discussions with the investment banking community to help support our efforts to make this goal a reality.
Please watch the video and read the formal press release below.
Med-X, Inc. Secures $100 Million Expansion Capital Commitment from Global Emerging Markets (GEM)
LOS ANGELES, Aug. 6, 2021 /PRNewswire/ -- Today, Med-X, Inc. (MED-X) announced a $100 million capital commitment from GEM Global Yield, LLC SCS (GGY), a Luxembourg-based private alternative investment group. Under the agreement, GGY will provide MED-X with a Share Subscription Facility of up to $100 million for a 36-month term following the public listing of MED-X's common stock.
Med-X will control the timing and maximum number of drawdowns and under this agreement can put a drawdown notice for up to $10MM worth of shares on the first day of trading. Concurrent with a public listing Med-X will issue warrants to GEM to purchase up to 4.0% of the common stock of the company. Med-X's flagship division, Nature-Cide, has developed a line of all-natural professional pest control applications. One of its pest control solutions for Vector Control, is continuously being tested by third parties with astounding recorded results. The products are set for expansion, from major distribution partners in in various regions around the globe.
"GEM's equity investment solidifies our business model as well as our long-term financial goals while reinforcing and furthering our mission to the world stage", states founder and COO Matthew Mills. "So far, we've been very successful with self-underwriting our Regulation A+ Offering, which has generated investments from more than 3,600 individuals over the last 4 years. This new $100MM capital commitment should allow the Company to advance on its Mergers & Acquisitions strategy, while propelling the brands in a manner where our mission of "Making a difference every day" will move to a whole new level", states Mills.
About Med-X, Inc.
Med-X, Inc. is a Nevada corporation formed in February 2014 to support the fast-paced environmentally friendly green scene products and services sectors, with its Nature-Cide, Thermal-Aid and Malibu Brands divisions as well as the emerging hemp and cannabis industry through such activities as compound identification and extraction of the identified cannabidiol (CBD) compounds for the present medical industry demand.
For more information regarding Med-X, Inc., please visit www.medx-rx.com, email firstname.lastname@example.org or call 818-349-2870
About The GEM Global Yield, LLC SCS Group
Global Emerging Markets ('GEM') is a $3.4 billion, alternative investment group with offices in Paris, New York and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 440 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities, and select venture investments. For more information: https://www.gemny.com
Jean-Luc Bonnefoy: email@example.com
Matthew Mills: firstname.lastname@example.org
DISCLAIMER AND FORWARD-LOOKING STATEMENTS
The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the Regulation A+ Offering Circular Securities Exchange Commission filings before making any investment in the Company.
This article may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.
SOURCE Med-X, Inc.
Med-X, Inc. Management Team Signs $86 Million Dollar Non-Binding Term Sheet to Bolster Long Term Growth and Prepare the Company for a Potential Public Listing
In this exciting Company update, COO and President, Matthew Mills informs shareholders on the status of several international deals, status of ecommerce growth, capital raising and announces an exciting signing of the Company's first non-binding Term Sheet with an investment bank for an 86 Million dollar equity drawdown, to support the Company’s growth initiatives, if and when the Company lists on a public exchange.
Growth in our digital ecommerce sales efforts continues its pace forward. New initiatives have recently been executed to continue to bolster B2C sales including the approval from Walmart Marketplace to enter the Walmart Fulfillment program.
Walmart is very selective when it comes to approving brands and companies to be included in this program, so we feel very confident that our products and customer service is making a difference in our customers' lives. Walmart is recognizing us, which is great news for our brands.
Walmart advertises to its fulfillment partners that customers should expect a 20% to 40% increase in sales by simply entering the program. We will keep you updated on this front in future updates as our team continues to dial this all in.
Progress also continues to be made on our international Nature-Cide positioning as the labels are currently under review to get approved by the Mexican and Australian governmental authorities. Products have already shipped to Terminix in the Caribbean and Antigua. The compliance and approval processes are critical for our growth internationally but our partners have a solid track record of bringing in new products, and we feel really good about the coming months as we continue to push through the red tape.
Matthew continues to speak with dozens of interested investment entities including VC’s, Angel investors, Family Offices and Investment Banks. Our partners at New Chip as well as our new broker-dealer, The Dalmore Group, have been actively making strong recommendations and introductions as the management team works tirelessly to find the right fit to assist our efforts to potentially take the Company to the public market.
Matthew has also initially agreed to an 86 Million dollar non-binding term sheet with a large investment bank who is committed to seeing our Company grow and bolster revenue once the Company is listed.
At this point, the Company fits all the criteria to list on the Nasdaq except for one item. We need an additional $4 million dollars in the bank to fully qualify. Many of our Accredited investors have recognized this opportunity and they have stepped up in a big way to support this mission.
This money is required so the Company can bridge the gap from private to public, as Matthew explains in the video.
“We are finally in a position where our business is of interest to the investment banking community, and we will continue pushing to line up the right partners. One thing we have learned over the years is to have as many irons in the fire as possible on all fronts. It’s inevitable that some of the relationships will flourish, and others will fizzle and not perform as expected. So, the only way we can move forward is to build an abundance of relationships amongst all of the inner workings of our business, until we find all the right performers,” states Matthew.
We are hopeful that all of our shareholders will also recognize this opportunity and spread the word by telling their friends, family and co-workers about our Company and how they can also get involved and get in on the ground floor before we potentially file for a listing on a public exchange.
As Matthew also says in the video, this is an exciting time and all of your support and the hard work from our team has really set the Company up for success and is setting a path for our goals. We would never be in this position without all the support from each and every one of our shareholders.
We thank you. We are all so grateful to have such an amazing group of people connected to this Company who support all of our work.
Also, please double-check your investor dashboard to make sure everything is matching up with your records. As we get closer to our end goal it will be critical that your contact information and investment information is accurate. Contact us if you notice any discrepancies.
SEC FIling - https://www.sec.gov/Archives/edgar/data/1620704/000147793221002683/medx_1k.htm
Thank you very much.
DISCLAIMER AND FORWARD-LOOKING STATEMENTS
The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company.
This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.